VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE AGREEMENT WITH A MAJOR INTERNATIONAL HUMAN VACCINE CORPORATION
Nantes & Lyon (France) - May 6th, 2013-VIVALIS (NYSE Euronext: VLS) announced today that it has signed an EB66® cell line research license agreement with one the world's largest human vaccine developers. The scope of this agreement is for the evaluation of the use of the EB66® cell line for the production of several vaccines in development and for vaccines currently commercialized, where the switch to the EB66® cell line would represent a replacement substrate for previously approved products. This agreement represents the fourth EB66® cell line agreement signed since the start of the 2013 calendar year.
Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, "We are very pleased to enter into this agreement with this organization demonstrating that the EB66®cell line continues to be the cell line of choice for vaccine manufacturing over traditional manufacturing systems, in both human and veterinary health vaccines. Of particular interest is the expansion into "legacy" products - those having already been approved - with the benefits of a manufacturing substrate like EB66® cells being highly appreciated. The scope of this agreement thus broadens the market opportunity for EB66® cells and we look forward to our partner advancing these products."
Financial terms of the agreement were not disclosed.
**********************
About VIVALIS (www.vivalis.com)
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of pathologies with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas:
- EB66® Cell Line
Vivalis offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, with a focus on monoclonal antibodies having enhanced cytotoxic activity. Clinical trials of EB66® produced vaccines are currently on-going in the USA and Japan. Through these programs, Vivalis receives upfront payments, clinical stage milestone payments and royalties on licensees' net sales.
- VIVA|Screen(TM) Human Antibody Discovery Platform
Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery phase, upfront payments, clinical stage milestone payments, and royalties on net sales of licensed antibodies that are commercially developed and sold by our clients.
Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Grimaud Group (ca. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Zoetis, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.
| VIVALIS Listed on Euronext Paris - Compartment B of NYSE Euronext Reuters: VLS.PA - Bloomberg: VLS FP Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes |
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document E, changes in economic conditions, the financial markets or the markets in which the company operates.
Contacts
VIVALIS NewCap
Franck Grimaud, CEO Financial communications agency
Email: investors@vivalis.com Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0) 1 44 71 94 91
